Bone turnover markers in patients with osteogenesis imperfecta

Bone

Volumn 34, Issue 6, 2004, Pages 1013-1016

  Braga, Vania ^a   Gatti, Davide ^a   Rossini, Maurizio ^a   Colapietro, Francesca ^a   Battaglia, Elia ^a   Viapiana, Ombretta ^a   Adami, Silvano ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b Ospedale di Valeggio   (Italy)

Author keywords

Free deoxypyridinoline; Markers of bone turnover; N telopeptides; Osteocalcin; Osteogenesis imperfecta; Phosphatase alkaline; Type I collagen

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; OSTEOCALCIN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE TURNOVER; CONTROLLED STUDY; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PROTEIN BLOOD LEVEL; URINE LEVEL;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE REMODELING; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOGENESIS IMPERFECTA;

EID: 2942525923     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.02.023     Document Type: Article

References (16)

1. Smith R. Osteogenesis imperfecta. Clin. Rheum. Dis. 12:1986;655-689
2. Sillence D.O., Senn A., Danks D.M. Genetic heterogeneity in osteogenesis imperfecta. J. Med. Genet. 16:1979;101-116
3. Ward L.M., Rauch F., Travers R., Chabot G., Azouz E.M., Lalic L., et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone. 31:2002;12-18
4. Glorieux F.H., Bishop N.J., Plotkin H., Chabot G., Lanoue G., Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. New Engl. J. Med. 339:1998;947-952
5. Plotkin H., Rauch F., Bishop N.J., Montpetit K., Ruck-gibis J., Travers R., et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J. Clin. Endocrinol. Metab. 85:2000;1846-1850
6. Astrom A., Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch. Dis. Child. 86:2002;356-364
7. Adami S., Gatti D., Colapietro F., Fracassi E., Braga V., Rossini M., et al. Intravenous neridronate in adults with osteogenesis imperfecta. J. Bone Miner. Res. 1:2003;126-130
8. Brenner R.E., Schiller B., Vetter U., Ittner J., Teller W.M. Serum concentrations of procollagen I C-terminal propetide, osteocalcin and insulin-like growth factor-I in patients with non-lethal osteogenesis imperfecta. Acta Paediatr. 82:1993;764-767
9. Brenner R.E., Vetter U., Bollen A.M., Morike M., Eyre D.R. Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J. Bone Miner. Res. 7:1994;993-997
10. Rauch F., Travers R., Parfitt A.M., Glorieux F.H. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 26:2000;581-589
11. Chines A., Petersen D.J., Schranck F.W., Whyte M.P. Hypercalciuria in children severely affected with osteogenesis imperfecta. J. Pediatr. 119:1991;51-57
12. Chines A., Boniface A., McAlister W., Whyte M.P. Hypercalciuria in osteogenesis imperfecta: a follow-up study to assess renal effects. Bone. 16:1995;333-339
13. Minisola S., Rosso R., Romagnoli E. Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J. Bone Miner. Res. 10:1995;335-336
14. Cepollaro C., Gonnelli S., Pondrelli C., Montagnani A., Bruni D., Gennari C. Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters. Calcif. Tissue Int. 65:1999;129-132
15. Shapiro J.R. Comments. J. Bone Miner. Res. 10:1995;338-339
16. Lund A.M., Hanser M., Kollerup G., Juul A., Teisner B., Skovby F. Collage-derived markers of bone metabolism in osteogenesis imperfecta. Acta Paediatr. 87:1998;1131-1137